Proinflammatory cytokines synergistically enhance the production of chemokine ligand 20 (CCL20) from rheumatoid fibroblast-like synovial cells in vitro and serum CCL20 is reduced in vivo by biologic disease-modifying antirheumatic drugs

Journal of Rheumatology

Volumn 36, Issue 11, 2009, Pages 2397-2402

  Kawashiri, Shin Ya ^a   Kawakami, Atsushi ^a   Iwamoto, Naoki ^a   Fujikawa, Keita ^a   Aramaki, Toshiyuki ^a   Tamai, Mami ^a   Arima, Kazuhiko ^a   Kamachi, Makoto ^a   Yamasaki, Satoshi ^a   Nakamura, Hideki ^a   Tsurumoto, Toshiyuki ^a   Kono, Masafumi ^b   Shindo, Hiroyuki ^c   Ida, Hiroaki ^a   Origuchi, Tomoki ^a   Eguchi, Katsumi ^a  

^a NAGASAKI UNIVERSITY   (Japan)

^b JAPANESE RED CROSS NAGASAKI GENBAKU HOSPITAL   (Japan)

^c NAGASAKI UNIVERSITY   (Japan)

Author keywords

Biologic disease modifying antirheumatic drugs; Chemokine ligand 20; Fibroblast like synovial cells; Proinflammatory cytokines; Rheumatoid arthritis

Indexed keywords

ALPHA INTERFERON; ATLIZUMAB; ETANERCEPT; GAMMA INTERFERON; INFLIXIMAB; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; FEMALE; FIBROBLAST; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYNOVIOCYTE; TH17 CELL; TREATMENT OUTCOME;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CELLS, CULTURED; CHEMOKINE CCL20; CYTOKINES; FEMALE; FIBROBLASTS; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-17; INTERLEUKIN-1BETA; INTERLEUKIN-6; MALE; MIDDLE AGED; RECEPTORS, INTERLEUKIN-6; SYNOVIAL MEMBRANE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 70450170213     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.090132     Document Type: Article

References (28)

1. Baba M, Imai T, Nishimura M, Kakizaki M, Takagi S, Hieshima K, et al. Identification of CCR6, the specific receptor for a novel lymphocyte-directed CC chemokine LARC. J Biol Chem 1997;272:14893-14898 (Pubitemid 27251760)
2. Horita K, Yoshitomi H, Hashimoto M, Maeda S, Teradaira S, Sugimoto N, et al. Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and its animal model. J Exp Med 2007;204:2803-2812 (Pubitemid 350179551)
3. Singh SP, Zhang HH, Foley JF, Hedrick MN, Farber JM. Human T cells that are able to produce IL-17 express the chemokine receptor CCR6. J Immunol 2008;180:214-221
4. Acosta-Rodriguez EV, Rivino L, Geginat J, Jarrossay D, Gattorno M, Lanzavecchia A, et al. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol 2007;8:549-551
5. Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 1999;103:1345-1352 (Pubitemid 29218305)
6. Tesmer LA, Lundy SK, Sarkar S, Fox DA. Th17 cells in human disease. Immunol Rev 2008;223:87-113.
7. Lubberts E. IL-17/Th17 targeting: On the road to prevent chronic destructive arthritis? Cytokine 2008;41:84-91.
8. Chabaud M, Page G, Miossec P. Enhancing effect of IL-1, IL-17, and TNF-a on macrophage inflammatory protein-3a production in rheumatoid arthritis: regulation by soluble receptors and Th2 cytokines. J Immunol 2001;167:6015-6020 (Pubitemid 33062800)
9. Ruth JH, Shahrara S, Park CC, Morel JC, Kumar P, Qin S, et al. Role of macrophage inflammatory protein-3a and its ligand CCR6 in rheumatoid arthritis. Lab Invest 2003;83:579-588 (Pubitemid 36457712)
10. Matsui T, Akahoshi T, Namai R, Hashimoto A, Kurihara Y, Rana M, et al. Selective recruitment of CCR6-expressing cells by increased production of MIP-3a in rheumatoid arthritis. Clin Exp Immunol 2001;125:155-161 (Pubitemid 32703379)
11. Kageyama Y, Ichikawa T, Nagafusa T, Torikai E, Shimazu M, Nagano A. Etanercept reduces the serum levels of interleukin-23 and macrophage inflammatory protein-3 alpha in patients with rheumatoid arthritis. Rheumatol Int 2007;28:137-143 (Pubitemid 350105857)
12. St. Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, et al. Active-controlled study of patients receiving infliximab for the treatment of rheumatoid arthritis of early onset study group: combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004;50:3432-3443
13. Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 2007;66:1162-1167 (Pubitemid 47309731)
14. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363:675-681 (Pubitemid 38296553)
15. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-324
16. van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996;39:34-40.
17. Weaver CT, Harrington LE, Mangan PR, Gavrieli M, Murphy KM. Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity 2006;24:677-688 (Pubitemid 43867371)
18. Hashizume M, Hayakawa N, Mihara M. IL-6 trans-signaling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-alpha and IL-17. Rheumatology 2008;47:1635-1640
19. Rose-John S, Scheller J, Elson G, Jones SA. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leukoc Biol 2006;80:227-236 (Pubitemid 44835496)
20. Romagnani S. Human Th17 cells. Arthritis Res Ther 2008;10:206.
21. Katz Y, Nadiv O, Beer Y. Interleukin-17 enhances tumor necrosis factor a-induced synthesis of interleukins 1, 6, and 8 in skin and synovial fibroblasts. Arthritis Rheum 2001;44:2176-2184
22. Okamoto H, Cujec TP, Yamanaka H, Kamatani N. Molecular aspects of rheumatoid arthritis: role of transcription factors. FEBS J 2008;275:4463-4470
23. Hirano T, Ishihara K, Hibi M. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene 2000;19:2548-2556 (Pubitemid 30339210)
24. Nishio S, Yamamoto T, Kaneko K, Tanaka-Matsumoto N, Muraoka S, Kaburaki M, et al. Pharmacokinetic study and Fc gamma receptor gene analysis in two patients with rheumatoid arthritis controlled by low-dose infliximab. Mod Rheumatol 2009;19:329-333
25. Nestorov I, Zitnik R, DeVries T, Nakanishi AM, Wang A, Banfield C. Pharmacokinetics of subcutaneously administered etanercept in subjects with psoriasis. Br J Clin Pharmacol 2006;62:435-445 (Pubitemid 44401526)
26. Iwamoto S, Iwai S, Tsujiyama K, Kurahashi C, Takeshita K, Naoe M, et al. TNF-alpha drives human CD14+ monocytes to differentiate into CD70+ dendritic cells evoking Th1 and Th17 responses. J Immunol 2007;179:1449-1457
27. Ma D, Zhu X, Zhao P, Zhao C, Li X, Zhu Y, et al. Profile of Th17 cytokines (IL-17, TGF-beta, IL-6) and Th1 cytokine (IFN-gamma) in patients with immune thrombocytopenic purpura. Ann Hematol 2008;87:899-904.
28. Mills KH. Induction, function and regulation of IL-17-producing cells. Eur J Immunol 2008;38:2636-2649